GMP approved factory,stable supplying, competitive price
*The following content is generated by AI and is for reference only.
Baloxavir marboxil, often referred to in research contexts as Baloxavir INTS or its active moiety baloxavir acid, represents a significant advancement in the treatment of influenza. Its chemical identity is defined by the molecular formula C27H18F3N3O5S and the CAS number 1940663-88-8 for the prodrug form. This compound functions as a cap-dependent endonuclease inhibitor, specifically targeting the PA subunit of the influenza virus RNA polymerase complex. Unlike neuraminidase inhibitors such as oseltamivir, which block viral release from host cells, baloxavir prevents the initiation of viral replication by cleaving the "cap" structures from host mRNA, a process essential for viral gene transcription.
Approved for clinical use, baloxavir marboxil is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours. It demonstrates efficacy against both Influenza A and B strains, including those resistant to other antiviral classes. The drug is administered orally as a single dose, offering a distinct advantage in patient compliance compared to multi-day regimens required by older therapies. Following ingestion, it undergoes rapid hydrolysis in the gastrointestinal tract to release the active baloxavir acid, which achieves high plasma concentrations quickly.
Beyond immediate therapeutic applications, baloxavir has shown promise in prophylactic settings for preventing influenza transmission within households. Its mechanism of action effectively reduces viral load in the upper respiratory tract, thereby shortening the duration of symptoms and limiting the spread of the virus. As seasonal flu remains a global health challenge, baloxavir stands as a crucial tool in the modern antiviral arsenal, providing a potent option for managing outbreaks and protecting vulnerable populations. Ongoing research continues to explore its potential against emerging strains and broader public health strategies.